Adrim 50mg Inj. 1`s

A qualified oncology team administers it into a rapidly flowing intravenous line under close cardiac monitoring.

Adrim 50mg Injection Ingredients and Usage

Adrim 50mg Injection contains doxorubicin hydrochloride, an anthracycline antibiotic belonging to the antitumor antibiotic drug class. Oncologists prescribe it for malignant lymphoma, gastrointestinal carcinoma, and acute myelogenous leukemia, often within combination chemotherapy regimens.

Adrim 50mg Injection also treats soft tissue and osteogenic sarcoma, Wilms tumor, lung cancer, and cancers of the bladder and cervix. It is given as a single intravenous injection, typically at 60 to 75 mg per square meter, with a specialist experienced in chemotherapy administration supervising treatment throughout.

How Does Adrim 50mg Injection Work?

Doxorubicin intercalates between DNA base pairs, forming a stable complex that interferes with nucleic acid synthesis. It also inhibits topoisomerase II, an enzyme cancer cells need to manage DNA structure during replication.

By disrupting DNA function through multiple mechanisms, Adrim 50mg Injection blocks cancer cell division and triggers cell death. This same interaction with topoisomerase II in heart muscle cells is the basis for the drug's dose related cardiac toxicity.

Adrim 50mg Injection Side Effects

Adrim 50mg Injection commonly causes blood count changes and digestive side effects.

• Low white blood cell and platelet counts

• Nausea and vomiting

• Hair loss

• Mouth sores

• Fatigue

• Red discoloration of urine for 1 to 2 days after the dose

• Temporary loss of menstrual periods

Warnings

• Adrim 50mg Injection can cause potentially fatal congestive heart failure, which may appear during treatment or years later; cardiac risk rises sharply as cumulative dose increases, reaching 6 to 20 percent at a total cumulative dose of 500 mg per square meter.

• Cardiac monitoring is required before starting treatment and periodically throughout, particularly in patients with prior anthracycline exposure, chest radiation, or use of other cardiotoxic drugs.

• Adrim 50mg Injection must be given into a rapidly flowing intravenous line and never by intramuscular or subcutaneous injection; severe tissue necrosis, blistering, and ulceration can occur if the drug leaks outside the vein.

• The medicine increases the risk of secondary acute myeloid leukemia and myelodysplastic syndrome, usually appearing within 1 to 3 years of treatment.

• Severe myelosuppression occurs at therapeutic doses and can lead to serious infection, septic shock, or hemorrhage; blood counts must be monitored closely.

• Avoid anthracycline based therapy for up to seven months after stopping trastuzumab where possible, since combined use raises cardiotoxicity risk.

• Adrim 50mg Injection is teratogenic; women of childbearing potential should avoid pregnancy during treatment, and it may cause temporary or permanent loss of menstrual periods.

Adrim 50mg Injection Storage Conditions

Store Adrim 50mg Injection as directed on the vial label, protected from light. Keep the vial in its original packaging until immediately before use. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.